Donna Cabral-Lilly has over 20 years of experience in the pharma and biotech space, with a proven track record for transitioning proof of concept pharmaceutical candidates through clinical development, marketing approval and post-marketing studies. Her particular expertise encompasses the areas of global CMC regulatory strategy and execution. Prior to joining Onxeo in 2023, Donna held Head of CMC positions with Oryn Therapeutics, Origin Biosciences (a Bridgebio company), Taaneh and Celator Pharmaceuticals. She contributed most recently to approvals for Nulibry and Vyxeos. She received her BA in Chemistry from Case Western Reserve University and her Ph.D. in biochemistry from Boston University.